Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3467-70. doi: 10.1016/j.bmcl.2011.03.093. Epub 2011 Apr 7.

Abstract

The continued optimization of a series of glucokinase activators is described, including attempts to understand the interplay between molecular structure and the composite parameter of unbound clearance. These studies resulted in the discovery of a new scaffold for glucokinase activators and further exploration of this scaffold led to the identification of GKA60. GKA60 maintains an excellent balance of potency and physical properties whilst possessing a significantly different, but complimentary, pre-clinical pharmacokinetic profile compared with the previously disclosed compound GKA50.

MeSH terms

  • Animals
  • Dogs
  • Drug Design*
  • Enzyme Activation / drug effects*
  • Enzyme Activators / chemical synthesis*
  • Enzyme Activators / pharmacology*
  • Glucokinase / metabolism*
  • Half-Life
  • Humans
  • Hypoglycemic Agents / chemistry*
  • Hypoglycemic Agents / pharmacology
  • Molecular Structure
  • Pyridines / pharmacology
  • Rats
  • Solubility
  • Structure-Activity Relationship

Substances

  • Enzyme Activators
  • Hypoglycemic Agents
  • Pyridines
  • glucokinase activator compound 50
  • Glucokinase